Lexicon Pharmaceuticals IncNASDAQ:LXRX
- LAST PRICE1.6600
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.6400/ 2
- Ask / Lots1.6500/ 245
- Open / Previous Close1.6200 / 1.6600
- Day Range
- 52 Week Range
- Volume1,674,064
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LXRX |
|---|---|---|
| 09:32 ET | 133190 | 1.6 |
| 09:34 ET | 2500 | 1.6 |
| 09:36 ET | 18772 | 1.605 |
| 09:38 ET | 15314 | 1.615 |
| 09:39 ET | 4850 | 1.615 |
| 09:41 ET | 20619 | 1.62 |
| 09:43 ET | 6709 | 1.63 |
| 09:45 ET | 12574 | 1.61 |
| 09:48 ET | 900 | 1.62 |
| 09:50 ET | 6871 | 1.625 |
| 09:52 ET | 21084 | 1.62 |
| 09:54 ET | 38068 | 1.6 |
| 09:56 ET | 9077 | 1.6 |
| 09:57 ET | 14891 | 1.595 |
| 09:59 ET | 18470 | 1.595 |
| 10:01 ET | 11377 | 1.605 |
| 10:03 ET | 7500 | 1.6001 |
| 10:06 ET | 748 | 1.605 |
| 10:08 ET | 3865 | 1.605 |
| 10:10 ET | 8000 | 1.6 |
| 10:12 ET | 2713 | 1.6 |
| 10:14 ET | 24747 | 1.615 |
| 10:15 ET | 2120 | 1.62 |
| 10:17 ET | 8035 | 1.62 |
| 10:19 ET | 3680 | 1.63 |
| 10:21 ET | 19313 | 1.6394 |
| 10:24 ET | 2091 | 1.635 |
| 10:26 ET | 13709 | 1.64 |
| 10:28 ET | 2202 | 1.635 |
| 10:30 ET | 3727 | 1.635 |
| 10:32 ET | 20806 | 1.62 |
| 10:33 ET | 1500 | 1.625 |
| 10:35 ET | 1202 | 1.62 |
| 10:37 ET | 12868 | 1.615 |
| 10:39 ET | 3020 | 1.62 |
| 10:42 ET | 9661 | 1.615 |
| 10:44 ET | 15326 | 1.62 |
| 10:46 ET | 4655 | 1.61 |
| 10:48 ET | 16095 | 1.605 |
| 10:50 ET | 50008 | 1.6 |
| 10:51 ET | 32458 | 1.605 |
| 10:53 ET | 719 | 1.605 |
| 10:55 ET | 7535 | 1.605 |
| 10:57 ET | 7902 | 1.605 |
| 11:00 ET | 17369 | 1.6 |
| 11:02 ET | 2180 | 1.605 |
| 11:04 ET | 427 | 1.605 |
| 11:06 ET | 2337 | 1.6 |
| 11:08 ET | 15580 | 1.61 |
| 11:09 ET | 2905 | 1.605 |
| 11:11 ET | 4190 | 1.6 |
| 11:13 ET | 1302 | 1.605 |
| 11:15 ET | 5030 | 1.6 |
| 11:18 ET | 1500 | 1.6 |
| 11:20 ET | 2914 | 1.61 |
| 11:22 ET | 41941 | 1.61 |
| 11:24 ET | 131242 | 1.605 |
| 11:26 ET | 11101 | 1.6 |
| 11:27 ET | 69044 | 1.605 |
| 11:29 ET | 5626 | 1.595 |
| 11:31 ET | 824 | 1.595 |
| 11:33 ET | 65181 | 1.59 |
| 11:36 ET | 17237 | 1.59 |
| 11:38 ET | 8923 | 1.595 |
| 11:40 ET | 600 | 1.59 |
| 11:42 ET | 2529 | 1.595 |
| 11:44 ET | 7250 | 1.59 |
| 11:45 ET | 3155 | 1.59 |
| 11:47 ET | 4243 | 1.59 |
| 11:49 ET | 4792 | 1.595 |
| 11:51 ET | 2879 | 1.5952 |
| 11:54 ET | 1871 | 1.595 |
| 11:56 ET | 17714 | 1.605 |
| 12:00 ET | 591 | 1.605 |
| 12:02 ET | 7400 | 1.605 |
| 12:03 ET | 3780 | 1.605 |
| 12:05 ET | 22146 | 1.61 |
| 12:07 ET | 21613 | 1.6199 |
| 12:09 ET | 289 | 1.62 |
| 12:12 ET | 179 | 1.62 |
| 12:14 ET | 978 | 1.62 |
| 12:16 ET | 120 | 1.615 |
| 12:18 ET | 10722 | 1.615 |
| 12:20 ET | 8892 | 1.61 |
| 12:21 ET | 1300 | 1.615 |
| 12:23 ET | 5546 | 1.62 |
| 12:25 ET | 1800 | 1.62 |
| 12:27 ET | 2560 | 1.61 |
| 12:30 ET | 1276 | 1.61 |
| 12:32 ET | 2887 | 1.61 |
| 12:34 ET | 16273 | 1.62 |
| 12:36 ET | 1055 | 1.63 |
| 12:39 ET | 10150 | 1.63 |
| 12:41 ET | 7765 | 1.63 |
| 12:43 ET | 17800 | 1.64 |
| 12:45 ET | 2956 | 1.64 |
| 12:48 ET | 5649 | 1.64 |
| 12:50 ET | 9023 | 1.64 |
| 12:52 ET | 30257 | 1.645 |
| 12:54 ET | 8394 | 1.65 |
| 12:56 ET | 8850 | 1.65 |
| 12:57 ET | 18650 | 1.65 |
| 12:59 ET | 58549 | 1.66 |
Jun 24, 2024
DJ Lexicon Pharma Price Target Maintained With a $10.00/Share by HC Wainwright & Co., from 6:46AM ET on Monday Jun 24, 2024 by Dow Jones
6:46AM ET on Monday Jun 24, 2024 by Dow Jones
Jun 21, 2024
DJ Lexicon Pharma Price Target Maintained With a $10.00/Share by HC Wainwright & Co., from 10:25AM ET on Friday Jun 21, 2024 by Dow Jones
10:25AM ET on Friday Jun 21, 2024 by Dow JonesLexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes, from 8:00AM ET on Friday Jun 21, 2024 by Dow Jones
8:00AM ET on Friday Jun 21, 2024 by Dow Jones
Jun 19, 2024
Jun 18, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Lexicon Pharmaceuticals Inc | 600.0M | -2.0x | --- |
Phathom Pharmaceuticals Inc | 600.0M | -2.3x | --- |
Mineralys Therapeutics Inc | 603.2M | -5.6x | --- |
Olema Pharmaceuticals Inc | 596.8M | -5.3x | --- |
Alumis Inc | 604.0M | -3.6x | --- |
Oculis Holding AG | 544.6M | -6.4x | --- |
Company Information
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.
Contact Information
- Headquarters
- 2445 Technology Forest Blvd, 11Th FloorTHE WOODLANDS, TX, United States 77381
- Phone
- 281-863-3000
- Fax
- 281-863-8088
Executives
- Independent Chairman of the Board
- Raymond Debbane
- President, Chief Financial Officer
- Jeffrey Wade
- Chief Executive Officer, Director
- Lonnel Coats
- Executive Vice President - Innovation and Chemical Sciences
- Alan Main
- Senior Vice President, General Counsel
- Brian Crum
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $600.0M |
|---|---|
Revenue (TTM) | $2.3M |
Shares Outstanding | 361.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.36 |
EPS | $-0.83 |
Book Value | $0.38 |
P/E Ratio | -2.0x |
Price/Sales (TTM) | 259.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -8,045.91% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
